Establishment of a stability indicating HPLC method for dronedarone hydrochloride in tablets and in cyclodextrin inclusion complexes: application to degradation kinetic studies

  • Ana Isa P. Marcolino
  • Laís E. Scheeren
  • Daniele R. Nogueira-Librelotto
  • Joana R. Fernandes
  • Andréa I. H. Adams
  • Leandro M. De Carvalho
  • Clarice M. B. RolimEmail author
Original Paper


The stability indicating HPLC method for the determination of dronedarone (DRO) hydrochloride in tablets and in inclusion complexes with cyclodextrin was carried out on a C18 column using a buffer solution (0.3% glacial acetic acid; pH 4.9) and acetonitrile (35:65, v/v) as mobile phase. The method validation according to ICH guidelines demonstrated acceptable results. Dronedarone was exposed to stress conditions, and drug-degradation kinetics was studied. Additionally, the degraded samples were analyzed by mass spectrometry and the preliminary toxicity against 3T3 cells was also determined. The results obtained evidenced that dronedarone degradation kinetics in alkaline conditions followed first-order reaction and that inclusion complexation with cyclodextrin reduced its chemical degradation. Among the samples exposed to stress conditions, only the photodegraded samples presented cytotoxic effects. Moreover, assay results were compared to a previously validated micellar electrokinetic chromatography method, showing non-significant difference (p > 0.05). The combination of HPLC, mass spectrometry and cytotoxicity study could be an important tool for the screening of DRO pharmaceutical forms, improving quality and safety in the development of novel drug delivery systems.


Cyclodextrin In vitro cytotoxicity Degraded samples Dronedarone High-performance liquid chromatography Inclusion complex 



This study was supported by the Brazilian National Council for Scientific and Technological Development (CNPq) [Grants 401069/2014-1 and 447548/2014-0] and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior).

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Supplementary material

11696_2018_643_MOESM1_ESM.docx (1 mb)
Supplementary material 1 (DOCX 1059 kb) Supplementary data Electronic Supplementary Material associated with this article, including HPLC/APCI–MS conditions, stress conditions, the robustness assay and the MS spectra, can be found in the online version of this paper


  1. Ahirrao VK, Patil CS, Bembalkar SR, Katariya MV, Sonnekar VS, Marathe RP, Nawale RB, Pawar RP (2012) Stress degradation studies of dronedarone in pharmaceutical dosage form by a validated stability-indicating LC method. J Chil Chem Soc 57:1272–1276. CrossRefGoogle Scholar
  2. Australian Public Assessment Report for Dronedarone Hydrochloride prepared by the Department of Health and Ageing (2010) Therapeutic Goods Administration (TGA), Australian Government. Accessed 6 Jan 2017
  3. Bhatt KK, Patelia EM, Amin I (2013) Development of a validated stability-indicating RP-HPLC method for dronedarone hydrochloride in pharmaceutical formulation. J Anal Bioanal Tech 4:161–169. CrossRefGoogle Scholar
  4. Chadha R, Bali A, Bansal G (2016) Identification and characterization of stress degradation products of dronedarone hydrochloride employing LC–UV/PDA, LC–MS/TOF and MS(n) studies. J Pharm Biomed Anal 118:139–148. CrossRefPubMedGoogle Scholar
  5. Felser A, Blum K, Lindinger PW, Bouitbir J, Krähenbühl S (2013) Mechanisms of hepatocellular toxicity associated with dronedarone—a comparison to amiodarone. Toxicol Sci 131:480–490. CrossRefPubMedGoogle Scholar
  6. Fernandes C, Encarnação I, Gaspar A, Garrido J, Borges F, Garrido EM (2014) Influence of hydroxypropyl-β-cyclodextrin on the photostability of fungicide pyrimethanil. Int J Photoenergy 2014:1–8. CrossRefGoogle Scholar
  7. Food and Drug Administration (2014) Food and Drug Administration labeling information: revised Multaq label, prepared by U.S Food and Drug Administration (FDA). Accessed 6 Jan 2017
  8. Fredenhagen A, Kühnöl J (2014) Evaluation of the optimization space for atmospheric pressure photoionization (APPI) in comparison with APCI. J Mass Spectrom 49:727–736. CrossRefPubMedGoogle Scholar
  9. Fülöp Z, Saokham P, Loftsson T (2014) Sulfobutylether- β-cyclodextrin/chitosan nano- and microparticles and their physicochemical characteristics. Int J Pharm 472:282–287. CrossRefPubMedGoogle Scholar
  10. Han SD, Jung SW, Jang SW, Jung HJ, Son M, Kim BM, Kang MJ (2015a) Preparation of solid dispersion of dronedarone hydrochloride with Soluplus(®) by hot melt extrusion technique for enhanced drug release. Chem Pharm Bull 63:295–299. CrossRefPubMedGoogle Scholar
  11. Han SD, Jung SW, Jang SW, Son M, Kim BM, Kang MJ (2015b) Reduced food-effect on intestinal absorption of dronedarone by self-microemulsifying drug delivery system (SMEDDS). Biol Pharm Bull 38:1026–1032. CrossRefPubMedGoogle Scholar
  12. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678. CrossRefPubMedGoogle Scholar
  13. ICH Q1A (R2) (2003) Stability testing of new drug substances and products. In: International conference on harmonization, Geneva, SwitzerlandGoogle Scholar
  14. ICH Q2 (R1) (2005) Validation of analytical procedures: text and methodology. In: International conference on harmonization, Geneva, SwitzerlandGoogle Scholar
  15. Jambhekar SS, Breen P (2016) Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today 21:356–362. CrossRefPubMedGoogle Scholar
  16. Kuo S, Menon K, Kundu RV (2014) Photosensitivity reaction from dronedarone for atrial fibrillation. Cutis 94:E10–E11PubMedGoogle Scholar
  17. Landge SB, Jadhav SA, Nimbalkara KP, Mali AC, Mathad VT (2013) Stability indicating RP-HPLC method for the determination of dronedarone hydrochloride and its potential process-related impurities in bulk drug and pharmaceutical dosage form. Am J Anal Chem 4:323–335. CrossRefGoogle Scholar
  18. Le Heuzey J-Y, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy J-M (2010) A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 21:597–605. CrossRefPubMedGoogle Scholar
  19. Marcolino AIP, Sangoi MS, Steppe M, Adams AIH, Rolim CMB (2013) Determination of dronedarone in the pharmaceutical dosage form by a stability-indicating micellar electrokinetic chromatography method. Anal Methods 5:3106–3113. CrossRefGoogle Scholar
  20. Mendes C, Buttchevitz A, Kruger JH, Kratz JM, Simões CMO, Benedet PO, Oliveira PR, Silva MAS (2016) Inclusion complexes of hydrochlorothiazide and β-cyclodextrin: physicochemical characteristics, in vitro and in vivo studies. Eur J Pharm Sci 83:71–78. CrossRefPubMedGoogle Scholar
  21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. CrossRefPubMedGoogle Scholar
  22. Mura P (2014) Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: a review. J Pharm Biomed Anal 101:238–250. CrossRefPubMedGoogle Scholar
  23. Mura P (2015) Analytical techniques for characterization of cyclodextrin complexes in the solid state: a review. J Pharm Biomed Anal 113:226–238. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Nogueira DR, Mitjans M, Infante MR, Vinardell MP (2011) Comparative sensitivity of tumor and non-tumor cell lines as a reliable approach for in vitro cytotoxicity screening of lysine-based surfactants with potential pharmaceutical applications. Int J Pharm 420:51–58. CrossRefPubMedGoogle Scholar
  25. Paim CS, Nogueira DR, Mitjans M, Lopez DR, Perez JL, Steppe M, Schapoval EES, Vinardell MP (2013) Biological safety studies of gemifloxacin mesylate and related substances. Photochem Photobiol Sci 12:805–812. CrossRefPubMedGoogle Scholar
  26. Popielec A, Loftsson T (2017) Effects of cyclodextrins on the chemical stability of drugs. Int J Pharm 531:532–542. CrossRefPubMedGoogle Scholar
  27. Pydimarry SPR, Cholleti VK, Vangala RR (2014) Stability-indicating UPLC method for determining related substances and degradants in dronedarone. J Chromatogr Sci 52:666–675. CrossRefPubMedGoogle Scholar
  28. Rebane R, Kruve A, Liigand P, Liigand J, Herodes K, Leito I (2016) Establishing atmospheric pressure chemical ionization efficiency scale. Anal Chem 88:3435–3439. CrossRefPubMedGoogle Scholar
  29. Rowe RC, Sheskey PJ, Quinn ME (2009) Handbook of pharmaceutical excipients, 6th edn. Pharmaceutical Press and American Pharmacists Association, London, pp 888–889Google Scholar
  30. Shabir GA (2003) Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A 987:57–66. CrossRefPubMedGoogle Scholar
  31. The United States Pharmacopeial Convention (2016) The United States Pharmacopeia and The National Formulary, USP 39-NF 34, RockvilleGoogle Scholar
  32. Tondepu N, Sait SS, Surendranath KV, Kaja RK, Kumar S (2012) A stability indicating U-HPLC method for Milnacipran in bulk drugs and pharmaceutical dosage forms. Am J Anal Chem 3:40–49. CrossRefGoogle Scholar
  33. Xie C, Yang S, Zhong D, Dai X, Chen X (2011) Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography–tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B 879:3071–3075. CrossRefGoogle Scholar
  34. Yoshioka S, Stella VJ (2002) Stability of drugs and dosage forms. Kluwer Academic Publishers, New YorkGoogle Scholar

Copyright information

© Institute of Chemistry, Slovak Academy of Sciences 2018

Authors and Affiliations

  • Ana Isa P. Marcolino
    • 1
  • Laís E. Scheeren
    • 1
  • Daniele R. Nogueira-Librelotto
    • 1
    • 2
  • Joana R. Fernandes
    • 1
  • Andréa I. H. Adams
    • 1
    • 2
  • Leandro M. De Carvalho
    • 3
  • Clarice M. B. Rolim
    • 1
    • 2
    Email author
  1. 1.Postgraduate Program in Pharmaceutical SciencesFederal University of Santa MariaSanta MariaBrazil
  2. 2.Department of Industrial PharmacyFederal University of Santa MariaSanta MariaBrazil
  3. 3.Department of ChemistryFederal University of Santa MariaSanta MariaBrazil

Personalised recommendations